Sesen Bio, Inc.

NasdaqCM:SESN Stock Report

Market Cap: US$2.6b

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Sesen Bio Management

Management criteria checks 3/4

Key information

Thomas Cannell

Chief executive officer

US$4.9m

Total compensation

CEO salary percentage11.34%
CEO tenure4.6yrs
CEO ownership0.05%
Management average tenure3.6yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

Sesen Bio and Carisma Therapeutics announce merger agreement

Sep 21

Sesen Bio GAAP EPS of -$0.16 misses by $0.03

Aug 08

Sesen Bio granted additional time period for regaining compliance

Jul 27

Sesen Bio slips after decision to pause U.S. studies for lead asset

Jul 18

Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives

Jun 02

We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully

Apr 17
We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate

Dec 05
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate

Sesen Bio: Interesting Price Drop After CRL

Nov 24

Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022

Nov 17

Sesen Bio: The Road Ahead

Aug 23

Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

Aug 12
Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat

Feb 18
News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat

Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?

Jan 26
Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?

Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook

Dec 21
Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook

CEO Compensation Analysis

How has Thomas Cannell's remuneration changed compared to Sesen Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2022n/an/a

-US$20m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

US$48m

Mar 31 2022n/an/a

US$54m

Dec 31 2021US$5mUS$558k

-US$336k

Sep 30 2021n/an/a

-US$24m

Jun 30 2021n/an/a

-US$118m

Mar 31 2021n/an/a

-US$119m

Dec 31 2020US$2mUS$533k

-US$23m

Sep 30 2020n/an/a

-US$41m

Jun 30 2020n/an/a

-US$32m

Mar 31 2020n/an/a

-US$60m

Dec 31 2019US$1mUS$520k

-US$107m

Sep 30 2019n/an/a

-US$81m

Jun 30 2019n/an/a

-US$82m

Mar 31 2019n/an/a

-US$36m

Dec 31 2018US$2mUS$198k

-US$34m

Compensation vs Market: Thomas's total compensation ($USD4.92M) is about average for companies of similar size in the US market ($USD6.44M).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.

CEO

Thomas Cannell (60 yo)

4.6yrs

Tenure

US$4,921,698

Compensation

Dr. Thomas R. Cannell, DVM, has been President, Chief Executive Officer and Director at Sesen Bio, Inc. since August 7, 2018. He served as Chief Operating Officer of Orexigen Therapeutics, Inc. since June...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas Cannell
President4.6yrsUS$4.92m0.048%
$ 1.2m
Monica Forbes
CFO & Treasurer3.6yrsUS$1.87m0.036%
$ 926.9k
Glen MacDonald
Chief Technology Officer6.1yrsUS$1.27m0.025%
$ 645.2k
Gregory L. Verdine
Co-Founderno datano datano data
Elly Ryu
Corporate Controller & Principal Accounting Officer1.9yrsno data0.050%
$ 1.3m
Erin Clark
Vice President of Corporate Strategy & Investor Relationsno datano datano data
Mark Sullivan
General Counsel3.6yrsUS$1.15m0.022%
$ 566.6k
Steve Barbera
Vice President of Market Access1.8yrsno datano data
David Brooks
Senior Vice President of Clinical Development5.8yrsno datano data
Dennis Kim
Chief Medical Officer4.3yrsUS$709.28kno data
Kirstin Anderson
Senior Director of Finance1.9yrsno datano data
Minori Rosales
Chief Development Officer1.2yrsno datano data

3.6yrs

Average Tenure

53yo

Average Age

Experienced Management: SESN's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Thomas Cannell
President4.6yrsUS$4.92m0.048%
$ 1.2m
Neal Shore
Member of Medical Advisory Boardno datano datano data
Jay Duker
Independent Chairman of the Board8.2yrsUS$251.28k0%
$ 0
Michael Jewett
Independent Director1.7yrsUS$469.77k0%
$ 0
Carrie Bourdow
Independent Director3.1yrsUS$215.91k0%
$ 0
Jason Keyes
Independent Director3.1yrsUS$219.01k0%
$ 0
Wassim Kassouf
Member of Medical Advisory Boardno datano datano data
Rian Dickstein
Member of Medical Advisory Boardno datano datano data
Thomas Keane
Member of Medical Advisory Boardno datano datano data
Donald Lamm
Member of Medical Advisory Boardno datano datano data
Alon Weizer
Member of Medical Advisory Boardno datano datano data
Michael O'Donnell
Member of Medical Advisory Boardno datano datano data

3.1yrs

Average Tenure

59.5yo

Average Age

Experienced Board: SESN's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/03/08 08:58
End of Day Share Price 2023/03/07 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sesen Bio, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Swayampakula RamakanthH.C. Wainwright & Co.
Christopher HowertonJefferies LLC